Table of Contents Table of Contents
Previous Page  280 / 916 Next Page
Show Menu
Previous Page 280 / 916 Next Page
Page Background


25th European Congress of Psychiatry / European Psychiatry 41S (2017) S238–S302

observe any inter-group differences in VFT P, SCWT (relative inhibi-

tion) or the GNG. In both patient groups, there appeared significant

correlations between their WCST and TMT scores. The general

neuropsychological profiles were similar in both groups. The DS

patients exhibited slightly greater interference within concept for-

mation and non-verbal cognitive flexibility. Such problems may

therefore be specific to that particular subset of schizophrenia. Our

results may be useful for the development of new rehabilitation

activities, which may increase the chance of the patients’ better

social functioning.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Relapse after first-episode psychosis:

A 3-year follow-up

E. Pereira

, M. Mota Oliveira , R. Guedes , M.J. Peixoto , I. Ferraz ,

C. Silveira

Centro Hospitalar de São João, Clinic of Psychiatry and Mental

Health, Porto, Portugal

Corresponding author.


Relapse after first-episode psychosis (FEP) is a fre-

quent problem, which can lead to patients’ poorer functioning and

response to treatment. Its prevention is one of the most important

and challenging targets in the treatment of psychotic disorders.


To characterize and evaluate relapse rates after FEP,

during the course of 3 years, of a group of patients admitted at a

psychiatry department.


A retrospective observational study was conducted.

Patients with a FEP between ages 18 to 40, admitted at the Clinic of

Psychiatry and Mental Health at São João Hospital Centre between

January 1, 2007 and September 30, 2013. Only patients with, at

least, 3 years of follow-up at the clinic were included.


Final sample of 58 patients, 39 of whichweremale (mean

age = 26.4 years). Forty patients were excluded by not completing

the 3 years follow-up at our department. The cumulative relapse

rates were 32.8% at 12months, 53.4% at 24 months and 63.8%

at 36 months. Patients with at least one relapse were younger

(25.78 years vs. 27.52 years) and had shorter periods of first hos-

pitalization (19.25 days vs. 23.52 days). These data did not reach

statistical significance. Non-adherence to prescribed medication

was described in 73.0% (


= 27) of patients at the time of relapse.

Eight of them (21.6%) presented with cannabis use.


Although no statistical significance was reached, our

findings are consistent with other studies. A future studywith a big-

ger sample would be important in achieving statistical significant


Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Medical comorbidity in schizophrenia

A. Pestana Santos

, J. A

mílcar Teixeira

Coimbra Hospital and University Centre, Psychiatry, Coimbra,


Corresponding author.

People with schizophrenia have higher prevalence of physical dis-

ease and its lifespan is shortened when compared with general

population. On average, they die 10 to 25 years earlier than general



The authors aimto identify themain comorbidities in people

with schizophrenia and define strategies to prevent it.


Literature review on Medline database.


People with schizophrenia have higher risk to have

hepatitis, cardiovascular diseases, diabetes, overweight, sexual

dysfunction and obstetric complications. This high vulnerability is

associated with higher rates of preventable risk factors, such as

smoking, alcohol consumption, use of street drugs, poor dietary

habits and lack of exercise. Moreover, some antipsychotic med-

ications used to treat schizophrenia have been associated with

higher incidence of physical disease. At last, there are risk factors

attributable to patients and healthcare services. Psychiatrists are

often not trained in detection and treatment of physical disease.

Despite this, there are several attitudes that can reduce the asso-

ciated morbidity and mortality in people with schizophrenia, such

as improving access to healthcare services, integrated healthcare

interventions to enable early diagnosis and promotion of healthy



Diagnosis and management of morbidity in people

with schizophrenia are more difficult because obstacles related to

the patient, the illness, the medical attitudes and the structure of

the healthcare services. Regardless these difficulties, the increased

frequency of physical disease in people with schizophreniamust be

valued due to improved detection and treatment of medical disease

will have significant benefits for their psychosocial function and

overall quality of life.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Empowerment with Psychotic

Symptoms Scale (EWPSS): Exploratory

study of the scale’s psychometric


M.J. Martins

1 , 2

, C. Carvalho

1 , 3

, P. Castilho


, A.T. Pereira



J. Gonc¸ alves

4 , R.


4 , A.M

. Pinto

2 ,

, C . M


2 ,

D. Carreiras

2 , 4 , M .


2 , A.




Faculty of Psychology and Educational Sciences of the University of

Coimbra, Cognitive and Behavioural Center for Research and

Intervention, Coimbra, Portugal


Faculty of Medicine of the University of Coimbra, Psychological

Medicine Department, Coimbra, Portugal


University of Azores, Department of Educational Sciences, Ilha São

Miguel, Portugal


University of Coimbra, Faculty of Psychology and Educational

Sciences, Coimbra, Portugal

Corresponding author.


Empowerment has been defined as the ability to act

autonomously, the willingness to take risks and being aware of

responsibility. The importance of this construct in psychosis has

been emphasized by recovery models. An integrant part of the

Clinical Interview for Psychotic Disorders (CIPD), the EWPSS is a

visual analog scale in which the participants assess their sense

of empowerment regarding symptoms (delusions, hallucinations,

negative symptoms and disorganization). EWPSS focuses on per-

sonal empowerment (self-worth and self-efficacy) as it could apply

to symptoms.


To preliminarily assess the psychometric properties of the

EWPSS in a sample of participants with psychosis.


The sample comprised 22 participants (68.2%

male), 72.7% single, 50% employed, between 19 and 47 years

old (M= 31.05; SD = 7.088), with 4–17 years of education

(M= 11.77; SD = 3.176). The most prevalent diagnosis was

schizophrenia (68.2%) and the participants had a mean of

1.90 hospitalizations (SD = 2.548). The participants were assessed

with the CIPD (EWPSS) and Depression, Anxiety and Stress



EWPSS has shown acceptable reliability for all dimen-

sions (with alphas ranging between .54 and .78). Empowerment